Lucy Bizien

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1994861/publications.pdf

Version: 2024-02-01

840776 1199594 4,693 12 11 12 citations h-index g-index papers 13 13 13 8505 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	12.6	1,983
2	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, .	12.6	1,749
3	Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Science Immunology, 2021, 6, .	11.9	357
4	Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. Journal of Experimental Medicine, 2021, 218, .	8.5	185
5	Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. Journal of Experimental Medicine, 2021, 218, .	8.5	130
6	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200413119.	7.1	110
7	Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. Journal of Experimental Medicine, 2022, 219, .	8.5	59
8	Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Science Immunology, 2023, 8, .	11.9	35
9	A loss-of-function <i>IFNAR1</i> allele in Polynesia underlies severe viral diseases in homozygotes. Journal of Experimental Medicine, 2022, 219, .	8.5	28
10	Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child. Proceedings of the National Academy of Sciences of the United States of America, $2021,118,$.	7.1	24
11	Respiratory viral infections in otherwise healthy humans with inherited IRF7 deficiency. Journal of Experimental Medicine, 2022, 219, .	8.5	21
12	Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study. BMC Infectious Diseases, 2022, 22, .	2.9	9